Sanara MedTech (SMTI) Projected to Release Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is expected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of $0.06 per share and revenue of $29.67 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Sanara MedTech (NASDAQ:SMTI) last posted its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The business had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $28.95 million. Sanara MedTech had a negative net margin of 29.15% and a positive return on equity of 29.72%.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $32.17 on Wednesday. Sanara MedTech has a 12 month low of $16.05 and a 12 month high of $35.52. The company has a debt-to-equity ratio of 5.86, a current ratio of 2.58 and a quick ratio of 2.30. The firm has a market capitalization of $295.64 million, a PE ratio of 145.77 and a beta of 1.23. The business’s fifty day moving average price is $34.42 and its 200 day moving average price is $25.61.

Analyst Ratings Changes

SMTI has been the subject of several analyst reports. Lake Street Capital cut Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a research report on Thursday, July 30th. Freedom Capital downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings raised Sanara MedTech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. HC Wainwright cut Sanara MedTech from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $35.00 in a research note on Thursday, July 30th. Finally, Wall Street Zen downgraded Sanara MedTech from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $35.00.

Sanara MedTech Company Profile

Sanara MedTech Inc is a medical technology company focused on developing, commercializing and distributing products used in wound care, surgical soft-tissue repair and tissue regeneration. The company serves healthcare providers treating acute, chronic and complex wounds, as well as patients requiring surgical tissue management.

Sanara’s product portfolio includes advanced wound-care and tissue-repair technologies such as CellerateRX products, FORTIFY tissue-repair products and other regenerative medicine solutions.